Cargando…
Increased risk of central line-associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists
Autores principales: | Meynaar, Iwan A., van Rijn, Simone, Ottens, Thomas H., van Burgel, Nathalie D., van Nieuwkoop, Cees |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171741/ https://www.ncbi.nlm.nih.gov/pubmed/35670819 http://dx.doi.org/10.1007/s00134-022-06750-w |
Ejemplares similares
-
Burnout, resilience and work engagement among Dutch intensivists in the aftermath of the COVID-19 crisis: A nationwide survey
por: Meynaar, Iwan A., et al.
Publicado: (2021) -
Central line-associated bloodstream infections in neonates
por: Cho, Hye Jung, et al.
Publicado: (2019) -
Treatment of central line-associated bloodstream infections
por: Guenezan, Jérémy, et al.
Publicado: (2018) -
The impact of central line insertion bundle on central line-associated bloodstream infection
por: Tang, Hung-Jen, et al.
Publicado: (2014) -
Effect of Central Line Bundle Compliance on Central Line-Associated Bloodstream Infections
por: Lee, Kyoung Hwa, et al.
Publicado: (2018)